glp 1 or metformin JCI Insight Glucagon-Like Peptide-1 Based Therapies: A

Jensterle M, Kocjan T, Kravos NA, Pfeifer M, Janez A

As shown in Figure 3B, 100 and 200 mg/kg cinchonine significantly reduced blood glucose at 15 min, and the AUC was also significant decreased compared with the mice gavaged with saline (Figure 3C)

Excessive ROS damages nucleic acids, proteins, and lipids to induce cell death, and sufficient intracellular GSH is critical for ROS clearance and cellular homeostasis [24,25,26,27,28,29,30]

Physiology, Testosterone

Biohacking culture People want to optimize performance and longevity Social media influence Peptides are widely promoted as recovery shortcuts Frustration with slow healing = lack of education by providers on how long tendon/ligament injuries can take to repair Athletes often seek ways to speed recovery beyond natural timelines A Major Concern: Unregulated Products Currently: most peptides are not approved by Health Canada or the FDA manufacturing is largely unregulated quality control is inconsistent This makes it difficult to verify: product purity dosing accuracy contamination risk Current Medical Consensus Peptides show biological promise in preclinical research but lack sufficient human evidence for routine clinical use Important unknowns include: dosing frequency duration long-term safety How Group23 Approaches Regenerative Medicine At Group23 Sports Medicine, we focus on treatments supported by the strongest evidence: structured rehabilitation programs under physiotherapy supervision load management and strength training ideally with strength and conditioning coach platelet-rich plasma (PRP) soft tissue adapted biocompatible hyaluronic acid injections SportVis see www.sportvis.ca high molecular weight cross linked hyaluronic acid injections Monovisc (see www.monovisc.ca), Synolis VA (see www.synolis.com) and Durolane (www.durolane.ca/en/) Blood Flow Restriction (BFR) therapy (see off the shelf and custom bracing strategies These treatments currently have far stronger clinical evidence than experimental peptide therapies